SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology
bioRxiv (Cold Spring Harbor Laboratory)
Abstract
ABSTRACT The sudden emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 from the Chinese province of Hubei and its subsequent pandemic spread highlight the importance of understanding the full molecular details of coronavirus infection and pathogenesis. Here, we compared a variety of replication features of SARS-CoV-2 and SARS-CoV and analysed the cytopathology caused by the two closely related viruses in the commonly used Vero E6 cell line. Compared to SARS-CoV, SARS-CoV-2 generated higher levels of intracellular viral RNA, but strikingly about 50-fold less infectious viral progeny was recovered from the culture medium. Immunofluorescence microscopy of SARS-CoV-2-infected cells established extensive cross-reactivity of antisera previously raised against a variety of nonstructural proteins, membrane and nucleocapsid protein of SARS-CoV. Electron microscopy revealed that the ultrastructural changes induced by the two SARS viruses are very similar and occur within comparable time frames after infection. Furthermore, we determined that the sensitivity of the two viruses to three established inhibitors of coronavirus replication (Remdesivir, Alisporivir and chloroquine) is very similar, but that SARS-CoV-2 infection was substantially more sensitive to pre-treatment of cells with pegylated interferon alpha. An important difference between the two viruses is the fact that - upon passaging in Vero E6 cells - SARS-CoV-2 apparently is under strong selection pressure to acquire adaptive mutations in its spike protein gene. These mutations change or delete a putative ‘furin-like cleavage site’ in the region connecting the S1 and S2 domains and result in a very prominent phenotypic change in plaque assays.
Authors 11
-
Leiden University Medical Center
Affiliation as printed
Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Section Electron Microscopy, Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands
-
Victorian Infectious Diseases Reference Laboratory · Peter Doherty Institute
Affiliation as printed
Virus Identification Laboratory, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, Australia
-
Victorian Infectious Diseases Reference Laboratory · Peter Doherty Institute
Affiliation as printed
Virus Identification Laboratory, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, Australia
-
Leiden University Medical Center
Affiliation as printed
Clinical Microbiology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Section Electron Microscopy, Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
-
Eric J. Snijder corresponding Aachen Molecular Virology Laboratory Department of Medical Microbiology
Leiden University Medical Center
Affiliation as printed
Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
Cited by 54 stored of 70
Cited by patents worldwide 17 (Lens.org)
-
BETACORONAVIRUS ATTENUATED STRAINEP4431599A4 2026-03-18 Pending
-
Tiled ClickSeq for targeted virus whole genome sequencingUS12359266B2 2025-07-15 Active
-
살아있는 약독화된 SARS-CoV-2 및 이의 제조 백신KR20250060275A 2025-05-07 Pending
-
Coronavirus vaccineUS12208136B2 2025-01-28 Active
-
Coronavirus vaccineUS12186387B2 2025-01-07 Active
-
Coronavirus vaccineUS12133899B2 2024-11-05 Active
-
A LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOFWO2024052336A1 2024-03-14 Pending
-
Coronavirus vaccineUS11925694B2 2024-03-12 Active
-
A LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOFEP4331602A1 2024-03-06 Discontinued
-
Coronavirus vaccineUS11878055B1 2024-01-23 Active
-
Terameprocol and nordihydroguaiaretic acid (NDGA) derivatives as coronavirus anti-viral agentsUS11844768B2 2023-12-19 Active
-
Therapeutic inhibition affinity of copper (II) complex and their diazenyl pyridinone heterocyclic ligands against SARS-CoV2US11786537B2 2023-10-17 Active
-
THERAPEUTIC INHIBITION AFFINITY OF COPPER (II) COMPLEX AND THEIR DIAZENYL PYRIDINONE HETEROCYCLIC LIGANDS AGAINST SARS-COV2US20230255981A1 2023-08-17 Active
-
Coronavirus vaccineUS11547673B1 2023-01-10 Active
-
Metodo per il rilevamento di patogeni virali con comportamento batteriofagico attraverso l’utilizzo della microscopia a fluorescenzaIT202200003620A1 2022-05-25 Pending
-
Methods and compositions for treating SARS-CoV-2 infection using carboxyamidotriazole orotateUS11318118B1 2022-05-03 Active
-
METHODS AND COMPOSITIONS FOR TREATING SARS-COV-2 INFECTION USING CARBOXYAMIDOTRIAZOLE OROTATEWO2022031451A1 2022-02-10 Patented